Related Experiment Video
Updated: Aug 14, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
[Differential malignant lymphoproliferative syndrome (LPS) diagnosis with flow cytometry: a study of 100 patients]
Insights
Flow cytometry accurately diagnoses 100 patients with lymphoproliferative disorders (LPD). Immunophenotypic findings aid in distinguishing B-cell chronic lymphocytic leukemia, hairy cell leukemia, and B-cell Non-Hodgkin lymphomas for targeted therapy.
Area of Science:
- Hematology
- Immunology
- Oncology
Context:
- Flow cytometry is crucial for diagnosing chronic lymphoproliferative disorders (LPD).
- Distinguishing between distinct LPD entities is vital for effective therapeutic decisions.
- This study analyzes immunophenotypic findings in 100 newly diagnosed LPD patients.
Purpose:
- To report the immunophenotypic findings of 100 patients with newly diagnosed LPD using two-color flow cytometry.
- To detail the application of a >15 monoclonal antibody panel for LPD diagnosis.
- To correlate clinical presentations with specific LPD diagnoses.
Summary:
- B-cell chronic lymphocytic leukemia (B-CLL) was identified in 74 patients (CD5+, CD23+, FMC7-).
- Hairy cell leukemia (HCL) and B-cell Non-Hodgkin lymphoma (B-NHL) were diagnosed in 6 and 13 patients, respectively.
- T-cell LPDs were less frequent (4 patients), including Sézary syndrome and T gamma lymphoproliferation.
Impact:
- Immunophenotypic diagnosis was confirmed histologically or molecularly in 17 patients with characteristic marker profiles.
- Clinical features like lymphadenopathy suggested mantle cell lymphoma, while splenomegaly indicated HCL.
- Early diagnosis of B-CLL (94%) allowed for conserved hematopoiesis, with 32% of LPDs detected via routine hematogram.
Abstract:
The clinical utility of flow cytometry in diagnosis of chronic lymphoproliferative disorders (LPD) is well established. Accurate diagnosis of related but still distinct entities is relevant to therapeutic decisions. We report on the immunophenotypic findings of 100 patients with a new diagnosis of LPD established by two-color flow cytometry. A panel of > 15 monoclonal antibodies was regularly applied. The characteristic immunophenotype of B-cell chronic lymphocytic leukemia (CD5+, CD23+, FMC7-) was found in 74 patients including one with Richter's transformation. Hairy cell leukemia (CD5-, CD11c+, CD103+) was diagnosed in 6, and B-cell Non-Hodgkin lymphoma (B-NHL) in 13 patients, respectively. 6 of the B-NHLs belonged to the entity of splenic lymphoma with villous lymphocytes (CD5-, CD23-, FMC7+) and 6 were identified as mantle cell lymphomas (CD5+, CD23-, FMC7+). One B-NHL was typed as follicular center cell lymphoma (CD5-, CD10+, FMC7+). Three B-cell LPDs without a characteristic marker profile were histologically further classifiable. With a total of 4 patients T-cell LPDs were much less frequent. Sézary syndrome (CD4+, CD8-, CD56-) and T gamma lymphoproliferation (CD4-, CD8+, CD16-, CD56-, CD57+) were diagnosed twice. In 17 patients with a characteristic marker profile (1 Richter's transformation, 5 hairy cell leukemias, 3 splenic lymphomas with villous lymphocytes, 4 mantle cell lymphomas, 4 T-cell proliferations) a further histological or molecular investigation confirmed the immunophenotypic diagnosis in all cases. Clinical presentation with lymphadenopathies and B-symptoms was mainly associated with the diagnosis of mantle cell lymphoma, whereas splenomegaly and infection were suggestive of hairy cell leukemia. 94% of the B-CLL patients were diagnosed at an early clinical stage with still conserved hematopoiesis, 32% of the LPDs were diagnosed following a routine hematogramm.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
09:44Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
Published on: September 5, 2019